{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35","upperLimit":"288","value":"174"},{"groupId":"OG001","lowerLimit":"57","upperLimit":"210","value":"210"},{"groupId":"OG002","lowerLimit":"59","upperLimit":"178","value":"170"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"Duration of response was defined as the number of days between the date of first tumor response assessment of objective response to the time of the first tumor response assessment of progressive disease (PD) or death due to any cause (date of first PD assessment or death - date of first objective response assessment + 1)","dispersionType":"Full Range","groups":[{"description":"Includes the Phase 1 dose-finding groups A, B, and C","id":"OG000","title":"Phase 1"},{"description":"Phase 2 Treatment Group B had 10 mg/m2 of pralatrexate followed the next day by 400 mg/m2 of gemcitabine administered once every 2 weeks. One cycle of pralatrexate and gemcitabine was 4 weeks in duration and consisted of 2 doses each of pralatexate and gemcitabine.","id":"OG001","title":"Phase 2 - Group B"},{"description":"Phase 2 Treatment Group C had 15 mg/m2 of pralatrexate followed 1 hour later by 600 mg/m2 of gemcitabine administered once every 2 weeks. One cycle of pralatrexate and gemcitabine was 4 weeks in duration and consisted of 2 doses each of pralatrexate and gemcitabine.","id":"OG002","title":"Phase 2 - Group C"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Response assessments were performed no less than every 3 cycles in the Phase 1 part of the study and every 8 weeks (± 1 week) in the Phase 2a part of the study","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}